Physical Model Evaluation of Topical Prodrug Delivery—simultaneous Transport and Bioconversion of vidarabine-5′-valerate I: Physical Model Development
- 1 November 1979
- journal article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 68 (11) , 1341-1346
- https://doi.org/10.1002/jps.2600681104
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Skin as an Active Metabolizing Barrier I: Theoretical Analysis of Topical BioavailabilityJournal of Pharmaceutical Sciences, 1977
- In Vitro Estimates of Topical BioavailabilityJournal of Pharmaceutical Sciences, 1977
- EFFECT OF A NOVEL ADENOSINE DEAMINASE INHIBITOR (CO‐VIDARABINE, CO‐V) UPON THE ANTIVIRAL ACTIVITY IN VITRO AND IN VIVO OF VIDARABINE (VIRA‐ATM) FOR DNA VIRUS REPLICATIONAnnals of the New York Academy of Sciences, 1977
- Antiviral Activity of Arabinosyladenine and Arabinosylhypoxanthine in Herpes Simplex Virus-Infected KB Cells: Selective Inhibition of Viral Deoxyribonucleic Acid Synthesis in the Presence of an Adenosine Deaminase InhibitorAntimicrobial Agents and Chemotherapy, 1976
- Effect of Adenosine Deaminase upon the Antiviral Activity In Vitro of Adenine Arabinoside for Vaccinia VirusAntimicrobial Agents and Chemotherapy, 1974
- Chemotherapy of Cutaneous Herpesvirus Infection of Hairless MiceJournal of Investigative Dermatology, 1973
- The Antiviral Activity of 9-β-D-Arabinofuranosyladenine (ARA-A)Chemotherapy, 1968
- The Role of the 5′-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine DeaminaseJournal of Medicinal Chemistry, 1967
- Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analoguesArchives of Biochemistry and Biophysics, 1966
- The toxicity of 9-β-D-arabinofuranosyladenine to purine-requiring Escherichia coliBiochimica et Biophysica Acta, 1962